Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

ion, or $0.11 per share, compared with net income of $7.9 million, or $0.14 per share, for the same prior year period. The net loss for the nine months ended September 30, 2008 includes a non-operating charge of $3.1 million that reflects an other than temporary decline in value of the Company's equity investments.

As of September 30, 2008, the Company had approximately $88.7 million in current and non-current unrestricted cash, cash equivalents and marketable securities.

2008 Financial Guidance

The Company has revised its royalty revenue upward from previous guidance for 2008 to range from $33 million to $36 million. The Company recognizes royalty revenue on a cash basis when it is received. The Company has reduced its anticipated milestone receipts relating to the sale of products to Mayne Pharma to $1.8 million for 2008. Research and development expenses for 2008 have been revised downward and are expected to total approximately $33 million to $35 million. The growth over 2007 continues to be influenced by increasing costs related to clinical trial programs such as MP-470, ongoing pre-clinical product development efforts and investments in the discovery, pre-clinical, manufacturing, regulatory and clinical development operations of the Company. The Company expects to record a charge during 2008 of approximately $5.2 million for acquired in-process research & development resulting from a milestone payment to the former Montigen stockholders. This payment is contingent on the filing of an Investigational New Drug (IND) application (and upon the IND going into effect) with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology. Selling, general and administrative expenses are expected to be lower from previous guidance and are forecasted to be approximately $12 million for 2008. Included in 2008 total operating expenses are non-cash stock-based compensation expenses of approximately $3 million. Based on th
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... YORK, April 7, 2011 Reportlinker.com announces that ... its catalogue: Industrial Biotechnology China ... The Chinese central government was reported ... emission-reduction" in the Twelfth Five-Year (2011-2015) Plan. This ...
... in Spanish . Tekniker-IK4 is ... based on carbonaceous nanoparticles for application to sectors such ... to detect the pressure of the driver,s foot, a ... capacity, self-lubricating engine components, a low-cost and fire-resistant construction ...
... Cephalon, Inc. (Nasdaq: CEPH ) has scheduled ... results for 5:00 p.m. EDT on Tuesday, May 3, 2011. ... 2011 results will be distributed by PRNewswire4:50 p.m. EDT , ... toConference Code Number 67208985:00 p.m. EDT , Conference call begins ...
Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1103 2Reportlinker Adds Industrial Biotechnology China News 1103 3New materials based on carbon nanoparticles 2
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Drug Administration (FDA) today issued a public health advisory ... to new safety information concerning an unapproved (i.e., "off-label") ... drugs are approved for the treatment of schizophrenia and ... behavioral disorders in elderly patients with dementia have shown ...
... and biochemistry are controlled by the central clock within ... The clock is synchronized to environmental cycles of light ... that adjusting to new light schedules takes several days, ... are not well understood. Researchers now report findings that ...
... Preliminary results from a large, randomized clinical trial ... breast cancer ?cancer that has spread from the ... that those patients who received bevacizumab (Avastin? in ... period before their cancer progressed than patients who ...
Cached Biology News:FDA Warns About Antipsychotic Drugs and Elderly 2After a time-shift, mixed signals from the circadian clock 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 3
... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... unique human proteins on a 1x3 ... all extracellular proteins (EP) according to ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., UNIchip ...
... for analytical performance , ... the ultimate in analytical,performance, the ... 810-MS features include: , ... providing reliable, routine, trace level,quantification. ...
Biology Products: